4th International Conference on Biochemical Markers for Brain Damage

描述(申请人提供)：本申请请求资助将于2005年9月8日至10日在缅因州布思贝港举行的第四届脑损伤生化标记物国际会议。脑损伤生化标记物(www.BMBD.lu.se)是一个由医生和科学家组成的国际组织，他们对使用血液和体液分析诊断和监测脑损伤感兴趣。每隔2-3年，我们将召开会议，介绍、讨论和辩论生化标记物的最新技术和创新，以及它们在脑损伤诊断、监测和神经保护中的应用。我们的小组涵盖了从儿科运动医学到老年中风康复的广泛的医学专科。会议将以世界知名的演讲者为特色，目标受众包括生物化学家、神经学家、神经外科医生、心脏外科医生、麻醉师、运动医学和急诊医生。演讲者已被特别挑选出来，为该领域带来新的见解。BMBD-2005的方案包括25个特邀讲座和40个从提交的摘要中挑选出来的演讲。其他摘要将在整个研讨会期间作为海报展出。会议主题包括急性创伤性/运动性脑损伤、中风、围手术期脑损伤、痴呆症和脱髓鞘疾病的生化标记物的使用。还将举办一场关于生物标记物开发和有效性的会议，旨在加强学术界和产业界之间的交流。妇女、少数族裔和残疾人将获得打折的注册费，并可以参加一个研讨会，以鼓励生物标记物研究的职业。本次会议已获得埃默里大学医学院批准的15个继续医学教育学分。该节目将在互联网上直播，并在埃默里大学CME网站上存档至少一年，任何有互联网接入的人都可以在那里随时观看。该项目还将发表在《神经创伤杂志》上。我们预计有150-200名注册者。

DESCRIPTION (provided by applicant): This application requests funding support for the 4th International Conference on Biochemical Markers for Brain Damage which will be held in Boothbay Harbor Maine, September 8 -10, 2005. Biochemical Markers for Brain Damage (www.BMBD.lu.se) is an international group of physicians and scientists interested in diagnosing and monitoring brain injury using blood and body fluid assays. Every 2-3 years we meet to present, discuss, and argue the latest technology and innovations in biochemical markers and their use in brain injury diagnosis, monitoring and neuroprotection. Our group covers a broad range of medical specialties from pediatric sports medicine to geriatric stroke rehabilitation. The meeting will feature world renowned speakers with a target audience of biochemists, neurologists, neurosurgeons, cardiac surgeons, anesthesiologists, sports medicine and emergency physicians. Speakers have been specifically selected to bring new insights into the field. The program for BMBD-2005 includes 25 invited lectures and 40 presentations selected from submitted abstracts. Other abstracts will be on display as posters throughout the symposium. The session topics include the use of biochemical markers for acute traumatic/sports brain injury, stroke, perioperative brain injury, dementia and demyelinating diseases. There will also be a session on biomarker development and validity that is designed to enhance communication between academia and industry. Women, minorities and persons with disabilities will receive a discounted registration fee and can attend a seminar to encourage careers in biomarker research. This meeting has been approved for 15 continuing medical education credits by Emory University School of Medicine. The program will be presented live on the Internet and archived for at least a year on the Emory University CME Website where it can be viewed at any time by anyone with Internet access. The program will also be published in the Journal of Neurotrauma. We expect 150-200 registrants.